Details of the Drug

General Information of Drug (ID: DM3JFIH)

Drug Name
Vancomycin
Synonyms Vancomycin (oral, MRSA), AuricX; Vancomycin (oral/pill, MSRA); Vancomycin (oral/pill, MSRA), AuricX/SRI International
Indication
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [1]
Bacterial endocarditis N.A. Approved [1]
Clostridioides difficile infection 1A04 Approved [1]
Methicillin-resistant staphylococci infection 1A00-1A09 Approved [2]
Neonatal sepsis N.A. Approved [1]
Staphylococcal pneumonia N.A. Approved [1]
Staphylococcus aureus infection N.A. Approved [1]
MRSA infection 1D01.0Y Investigative [3]
Skin infection 1F28-1G0Z Investigative [1]
⏷ Show the Full List of Indication(s)
Affected Organisms
Enteric bacteria and other eubacteriaTreponema pallidumStreptococcus pyogenesNeisseria gonorrhoeaeMycoplasma pneumoniaeLegionella pneumophilaCorynebacterium diphtheriaeChlamydia psittaciChlamydia trachomatisChlamydia pneumoniaeBordetella pertussis
ATC Code
A07AA09: Vancomycin
A07AA: Antibiotics
A07A: INTESTINAL ANTIINFECTIVES
A07: ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A: ALIMENTARY TRACT AND METABOLISM
J01XA01: Vancomycin
J01XA: Glycopeptide antibacterials
J01X: OTHER ANTIBACTERIALS
J01: ANTIBACTERIALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
S01AA28: Vancomycin
S01AA: Antibiotics
S01A: ANTIINFECTIVES
S01: OPHTHALMOLOGICALS
S: SENSORY ORGANS
Structure
3D MOL is unavailable 2D MOL
Chemical Identifiers
Formula
C66H75Cl2N9O24
Canonical SMILES
CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
InChI
1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1
InChIKey
MYPYJXKWCTUITO-LYRMYLQWSA-N
Cross-matching ID
PubChem CID
14969
ChEBI ID
CHEBI:28001
CAS Number
1404-90-6
UNII
6Q205EH1VU
DrugBank ID
DB00512
TTD ID
D0B1IV
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
VanA ligase (vanA) DEOFMQ7 Q0WYK7_ENTFL Substrate [4]
VanA ligase (vanA) DEO97D6 VANA_ENTFC Substrate [4]
VanA ligase (vanA) DEN6VO0 A0A376GZ73_ENTGA Substrate [5]
VanA ligase (vanA) DEO8E75 A0A437UFE2_ENTAV Substrate [4]
VanA ligase (vanA) DESOXHP A0A4U9YK96_ENTCA Substrate [6], [5]
VanB ligase (vanB) DER7KFQ VANB_ENTFA Substrate [4]
VanB ligase (vanB) DE27YVU Q58F99_ENTFC Substrate [4]
VanG ligase (vanG) DEPN8F9 A0A076YRI6_STRAG Substrate [7]
VanC2 ligase (vanC) DEIF4P9 VANC_ENTGA Substrate [8]
D-alanylalanine synthetase (ddl) DE035GU A0A1Q6S944_9FIRM Substrate [7]
VanB ligase (vanB) DEMDEJ8 Q58F99_ENTFC Substrate [9]
VanB ligase (vanB) DE2GMEK Q58F99_ENTFC Substrate [9]
VanC2 ligase (vanC) DEH73ZC Q47720_ENTCA Substrate [10]
VanG ligase (vanG) DEPH3S7 A0A076ZC24_STRAP Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Gene/Protein Processing [11]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Gene/Protein Processing [12]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB) OT17HGXJ DMB_HUMAN Gene/Protein Processing [12]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Gene/Protein Processing [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Vancomycin FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
4 Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
5 Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother. 1994 Jul;38(7):1675-7.
6 vanA in Enterococcus faecium, Enterococcus faecalis, and Enterococcus casseliflavus detected in French cattle. Foodborne Pathog Dis. 2009 Nov;6(9):1107-11.
7 vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio. 2014 Jul 22;5(4):e01386-14.
8 Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine:D-alanine ligase-related protein necessary for vancomycin resistance. Gene. 1992 Mar 1;112(1):53-8.
9 vanI: a novel D-Ala-D-Lac vancomycin resistance gene cluster found in Desulfitobacterium hafniense. Microb Biotechnol. 2014 Sep;7(5):456-66.
10 Bacterial resistance to vancomycin: overproduction, purification, and characterization of VanC2 from Enterococcus casseliflavus as a D-Ala-D-Ser ligase. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10040-4.
11 [Successful treatment of MRSA-associated glomerulonephritis with antibiotic therapy]. Nihon Jinzo Gakkai Shi. 2003;45(1):37-41.
12 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.